Rebecca McFarland, MD
Cardiovascular Disease · Louisville, KYNPI 1265420996
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for cardiovascular disease clinicians in KY, where the typical reported total is $2,503.
Across 143 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$329
- E.r. Squibb & Sons, L.L.C.$291
- Johnson & Johnson$269
- Novartis$246
- Astellas Pharma US Inc$236
- Medtronic$146
- plus $729 from 21 others
Across 2 payments — averaging $2642.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
What the payments were for
- Food & beverage$2,12094%
- Education$1266%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $329 |
| E.r. Squibb & Sons, L.L.C. | 21 | $291 |
| Johnson & Johnson | 24 | $269 |
| Novartis | 22 | $246 |
| Astellas Pharma US Inc | 11 | $236 |
| Medtronic | 1 | $146 |
| Abbott | 1 | $86 |
| Boehringer Ingelheim | 4 | $83 |
| AstraZeneca | 5 | $77 |
| Amgen | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Lantheus Medical Imaging, Inc. | 3 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Novo Nordisk | 2 | $33 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $27 |
| Vital Connect, Inc | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Merck | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Simulus$146
How this compares
$2,246 in reported general payments places this provider in the 45th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 404 | $444,804 |
| XareltoRivaroxaban | 175 | $230,526 |
| EntrestoSacubitril/Valsartan | 142 | $184,463 |
| JardianceEmpagliflozin | 79 | $83,523 |
| Repatha SyringeEvolocumab | 33 | $42,843 |
| Repatha SureclickEvolocumab | 34 | $28,396 |
| Praluent PenAlirocumab | 24 | $16,072 |
| FarxigaDapagliflozin Propanediol | 13 | $14,048 |
| Metoprolol Succinate | 709 | $10,706 |
| Rosuvastatin Calcium | 431 | $5,538 |
| Losartan Potassium | 448 | $4,022 |
| Valsartan | 140 | $3,451 |
| Atorvastatin Calcium | 423 | $3,402 |
| Potassium Chloride | 129 | $3,197 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $2,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $329 | $444,804404 claims |
| Johnson & JohnsonXarelto | $269 | $230,526175 claims |
| NovartisEntresto | $246 | $184,463142 claims |
| Boehringer IngelheimJardiance | $83 | $83,52379 claims |
| AstraZenecaFarxiga | $77 | $14,04813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Louisville
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- John HarrisLouisville$129K
- Rohan SamsonLouisville$94K
- Vipul PanchalLouisville$39K
- Steven RaibleLouisville$30K
- Chandhiran RangaswamyLouisville$19K
- Joseph LashLouisville$16K
- Shanker ChandiramaniLouisville$16K
- Pradeep SinghLouisville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.